Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer

Eur J Cancer. 2019 Jul:115:107-110. doi: 10.1016/j.ejca.2019.04.022. Epub 2019 May 24.

Authors

Maxime Fouchard¹, Helene Jantzem², Gilles Quere¹, Renaud Descourt¹, Gilles Robinet¹, Pierre-Guillaume Poureau³

Affiliations

¹ Department of Oncology, University Hospital, Brest, France.
² Department of Pharmacovigilance, University Hospital, Brest, France.
³ Department of Oncology, University Hospital, Brest, France. Electronic address: pierre-guillaume.poureau@chu-brest.fr.

PMID: 31132740
DOI: 10.1016/j.ejca.2019.04.022

No abstract available

Keywords: Cholangitis; Immune adverse event; Immunotherapy.

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma of Lung / drug therapy*
Adenocarcinoma of Lung / immunology
Adenocarcinoma of Lung / secondary
Adrenal Cortex Hormones / therapeutic use
Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal, Humanized / adverse effects
Antineoplastic Agents, Immunological / adverse effects*
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / immunology
Carcinoma, Non-Small-Cell Lung / secondary
Carcinoma, Squamous Cell / drug therapy*
Carcinoma, Squamous Cell / immunology
Carcinoma, Squamous Cell / secondary
Cholagogues and Choleretics / therapeutic use
Cholangitis / chemically induced*
Cholangitis / diagnosis
Cholangitis / drug therapy
Cholangitis / immunology
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / immunology
Lung Neoplasms / pathology
Male
Middle Aged
Nivolumab / adverse effects
Treatment Outcome
Ursodeoxycholic Acid / therapeutic use

Substances

Adrenal Cortex Hormones
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Cholagogues and Choleretics
durvalumab
Nivolumab
Ursodeoxycholic Acid
pembrolizumab
tremelimumab